Nanrilkefusp alfa

N/A

Report date: 2025/01/09 20:00:05

Base Information

Drug NameNanrilkefusp alfa
Drug Alias NameRLI-15SO-C101CYP-0150SOT-101
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 receptor beta chain agonistsInterleukin-2 receptor subunit gamma agonists
TargetsInterleukin-2 receptor beta chainInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsMicrosatellite instability-high cancerUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSotio Biotech AG
Active IndicationsN/A
Inactive IndicationsMicrosatellite instability-high cancerUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[21] 

Other Information

ATC CodeN/A
Related LinksN/A